Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 66.7%, free cash flow grew 62.1% and total debt rose 10.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow STIM
Neuronetics, Inc. (STIM) EV/Sales
As of 16 October 2026, Neuronetics, Inc. (STIM) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from −0.3× (March 2020) to 10.0× (October 2018); the current reading is higher than 51% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (31.81%) |
| FY2024 | 1.3× | 21.83% |
| FY2023 | 1.1× | (49.44%) |
| FY2022 | 2.2× | 125.36% |
| FY2021 | 1.0× | (75.49%) |
| FY2020 | 3.9× | 564.30% |
| FY2019 | 0.6× | (69.95%) |
| FY2018 | 2.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (9.46%) |
| Mar 2026 | 1.0× | 13.20% |
| Dec 2025 | 0.9× | (48.12%) |
| Sep 2025 | 1.8× | (30.83%) |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RXST RxSight, Inc. compare | 0.0× |
| INGN Inogen, Inc compare | 0.2× |
| QTRX Quanterix Corporation compare | 0.3× |
| OWLT Owlet, Inc. compare | 0.9× |
| STIM Neuronetics, Inc. | 1.2× |
| MXCT MaxCyte, Inc. compare | 1.2× |
| APYX Apyx Medical Corporation compare | 2.2× |
| PROF Profound Medical compare | 9.9× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)